Subscribe To
Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
— CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 — — CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 — — CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 — — $317.0 million in cash, cash equivalents, […] The post Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update appeared first on ForexTV...
Read More
Posted: Mar 9 2023, 22:09
Author Name: forextv
Views: 102037